Ozempic Prior Authorization Denied? Here's What to Do

Ozempic (semaglutide) is one of the most frequently denied medications in the United States. With a list price exceeding $900 per month, insurers aggressively use prior authorization to limit prescriptions. But a denial is not the end of the road. Ozempic PA denials are regularly overturned when you know what to submit.

Why Ozempic Gets Denied

The most common reasons insurers deny Ozempic prior authorization:

• Step therapy required: The insurer wants you to try metformin, sulfonylureas, or other cheaper diabetes medications first
• Diagnosis mismatch: Ozempic is FDA-approved for type 2 diabetes, not weight loss. If your diagnosis code suggests weight management, the PA will be denied. (Wegovy, the weight-loss formulation, requires a separate PA.)
• BMI not documented: Some insurers require a documented BMI above a threshold even for diabetic patients
• A1C requirements not met: Many insurers require a documented A1C above 7.0% despite your doctor's clinical judgment
• Preferred alternative on formulary: The insurer prefers a different GLP-1 (like Trulicity or Victoza) and requires you to try it first

Step 1: Check the Denial Reason

Read your denial letter carefully. The specific reason determines your appeal strategy. If the denial is for step therapy, you need documentation of prior medication trials. If it is for medical necessity, you need clinical evidence supporting Ozempic specifically. If it is a formulary issue, you may need a formulary exception request rather than a standard appeal.

Step 2: Gather Your Evidence

A successful Ozempic appeal typically includes:

• A1C history showing inadequate glycemic control on current medications
• Complete medication history documenting which diabetes drugs you have tried, the dates, dosages, and why each was insufficient or caused side effects
• Cardiovascular risk documentation: The SUSTAIN-6 and SELECT trials showed semaglutide reduces major cardiovascular events. If you have CVD risk factors, cite this evidence.
• ADA Standards of Medical Care recommending GLP-1 receptor agonists for patients with type 2 diabetes who have atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease
• Weight and BMI records if the insurer requires them

Step 3: Have Your Doctor Write the Appeal

The physician letter should specifically address:

• Why Ozempic (semaglutide) is preferred over other GLP-1 medications for this patient
• The patient's complete medication history including trials and failures
• Cardiovascular benefit data from the SUSTAIN clinical trial program
• The ADA treatment algorithm showing where GLP-1 agonists are recommended
• Consequences of delaying or denying this medication (worsening A1C, increased CV risk)

Step 4: Know the Insurer's PA Criteria

Each major insurer publishes Ozempic-specific PA criteria. Common requirements:

Your appeal should demonstrate that you meet the insurer's own published criteria, or explain with clinical evidence why an exception is warranted.